Drug intelligence / Profile preview

aripiprazole + sertraline

Development stage: Phase 4
Lead developer: Otsuka Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination formulation of aripiprazole (an atypical antipsychotic) and sertraline (a selective serotonin reuptake inhibitor) developed for the treatment of major depressive disorder and bipolar depression. It combines serotonin reuptake inhibition from sertraline with modulation of dopamine and serotonin receptors from aripiprazole.

Other names: ASC-01ASC01ASC 01aripiprazole/sertraline combination drugsertraline/aripiprazole

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on aripiprazole + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aripiprazole + sertraline.